Sarah E. PanzerUniversity of Wisconsin-Madison, Madison, Wisconsin, United States;Sancia K. FergusonUniversity of Wisconsin-Madison, Madison, Wisconsin, United States;Shivani GargUniversity of Wisconsin-Madison, Madison, Wisconsin, United States;
Membranous nephropathy (MN) is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN. However, its response rate is merely 60% during a follow-up period of up to 24 months. Obinutuzumab is a type Ⅱ humanized anti-...
100 Furie RA, et al. Ann Rheum Dis 2022;81:100–107. doi:10.1136/annrheumdis-2021-220920Systemic lupus erythematosusCLINICAL SCIENCEB- cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double- blind, placebo- controlled trialRichard A Furie, 1 Gust...
First-Ever Treatment for Lupus Nephritis Wins FDA Approval Roche announced this week that the U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis,... A Reyes 被引量: 0发表: 2019年 ...
SUN-374 B-CELL DEPLETION AND RESPONSE IN A RANDOMIZED, CONTROLLED TRIAL OF OBINUTUZUMAB FOR PROLIFERATIVE LUPUS NEPHRITIS - ScienceDirectIntroduction: Previous analyses identified associations between the degree of B-cell depletion and achievement of renal response in lupus nephritis (LN). NOBILITY ...
LUPUS nephritisCOMBINATION drug therapyCONFIDENCE intervalsMONOCLONAL antibodiesMYCOPHENOLIC acidTREATMENT effectivenessObjective. To determine whether adding obinutuzumab to standard-of-care lupus nephritis (LN) therapy could improve the likelihood of long-term preservation of kidney function and do so with ...
Case presentation: We present the severe case report of a patient who was diagnosed with lupus nephritis (LN) with gastrointestinal involvement and developed acute renal failure. The patient responded to the first dose of obinutuzumab but failed to achieve a complete response to ...
Kidney-Related Outcomes in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of the Phase 2 NOBILITY Trialdoi:10.1681/ASN.20233411S19bBrad H. RovinDepartment of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH;Jorge Alfonso Ross Terres...
AB0423 nobility,a phase 2 trial to assess the safety and efficacy of obinutuzumab,a novel type 2 antiCD20 monoclonal antibody (MAB),in patients (PTS)with ISN/RPSclass III or IV lupus nephritis (LN). Schindler T,Rovin B,Furie R,et al. Annals of the Rheumatic Diseases . 2016...